Results 171 to 180 of about 2,242,189 (260)

Tamoxifen resistance-related ceRNA network for breast cancer. [PDF]

Front Cell Dev Biol, 2022
Qiao Z, Xing Y, Zhang Q, Tang Y, Feng R, Pang W.   +5 more
europepmc   +1 more source

Mitochondria as the Hub of Apoptosis: A Comprehensive Insight From Mitochondria to Interactions With Other Organelles

MedComm, Volume 7, Issue 9, September 2026.
Mitochondria is the hub of apoptosis in various diseases. The disruption of mitochondrial structure (including membrane rupture, cristae remodeling, and mitochondrial membrane lipid redistribution), the imbalance of mitochondrial dynamics (including fusion and fission, autophagy), the release, disruption, and mutation of mitochondria DNA, as well as ...
Rubin Tan, Jinming Zhao, Rong Wang, Yue Shi, Zaozao Chen, Yixuan Ma, Na Li, Wenqing Duan, Duo Lin, Chunxiang Zhang   +9 more
wiley   +1 more source

Dual action of pyrimidine derivatives: Targeting tamoxifen resistance in breast cancer. [PDF]

Transl Oncol
Yuan J, Wang G, Beeraka NM, Zhang H, Wang Q, Zhang D, Wang M, Ravish A, Chinnathambi A, Alharbi SA, Rangappa KS, Nikolenko VN, Basappa B, Yang L.   +13 more
europepmc   +1 more source

Metabolism in Tumor: Mechanisms and Therapeutic Perspectives

MedComm, Volume 7, Issue 9, September 2026.
Tumor metabolic reprogramming converges on three hubs—the SREBP1/2–FASN–SCD1 lipogenic axis, the HIF‐1α–GLUT1–LDHA glycolytic axis, and the LDLR–SCARB1–LXR cholesterol system—which integrate transcriptional, epigenetic (histone lactylation, m6A), and microenvironmental inputs to generate metabolic plasticity, immune evasion, and therapy resistance ...
Jia‐Chen Cheng, Yi‐Xuan Hu, Xiang‐Chun Huang, Shan Jiang, Jie‐Lin Wang, Yang Zhao, Shuo Chen   +6 more
wiley   +1 more source

Synergistic Combination of Tamoxifen-Tetraphenylethylene Co-Assembled Micelles and Orlistat-Induced Lipid Droplet Inhibition to Overcome Tamoxifen Resistance. [PDF]

Adv Healthc Mater
Park JY, Lee J, Kim YY, Lee S, Kim Y.
europepmc   +1 more source

Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer. [PDF]

Cell Death Dis, 2023
Jiang C, Zhu Y, Chen H, Lin J, Xie R, Li W, Xue J, Chen L, Chen X, Xu S.   +9 more
europepmc   +1 more source

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

In Silico Analysis Reveals MDM2 as a Potential Target of Ursolic Acid for Overcoming Tamoxifen Resistance in Breast Cancer. [PDF]

Asian Pac J Cancer Prev
Jati YS, Sekarini DN, Zulkepli NA, Putri DDP.   +3 more
europepmc   +1 more source

SRSF5 Regulates the Expression of BQ323636.1 to Modulate Tamoxifen Resistance in ER-Positive Breast Cancer. [PDF]

Cancers (Basel), 2023
Tsoi H, Fung NN, Man EPS, Leung MH, You CP, Chan WL, Chan SY, Khoo US.   +7 more
europepmc   +1 more source

Nanoparticle‐Mediated Therapy for Glioma: Advances and Prospects

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Various nanocarriers, including liposomes, dendrimers, exosomes and gold nanoparticles, are designed to penetrate the blood‐brain barrier and deliver chemotherapy, radiotherapy, immunotherapy, gene therapy, phototherapy, magnetic hyperthermia and sonodynamic therapy for glioma.
Wenqian Jiang, Jing Fei, Rangrang Fan, Haifeng Chen, Liangxue Zhou, Gang Guo   +5 more
wiley   +1 more source